Cargando…
Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes
Numerous studies suggest that rapamycin treatment promotes insulin resistance, implying that rapamycin could have negative effects on patients with, or at risk for, type 2 diabetes (T2D). New evidence, however, indicates that rapamycin treatment produces some benefits to energy metabolism, even in t...
Autores principales: | Reifsnyder, Peter C., Flurkey, Kevin, Te, Austen, Harrison, David E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191889/ https://www.ncbi.nlm.nih.gov/pubmed/27922820 http://dx.doi.org/10.18632/aging.101117 |
Ejemplares similares
-
Rapamycin/metformin co‐treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice
por: Reifsnyder, Peter C., et al.
Publicado: (2022) -
Rapamycin Ameliorates Nephropathy despite Elevating Hyperglycemia in a Polygenic Mouse Model of Type 2 Diabetes, NONcNZO10/LtJ
por: Reifsnyder, Peter C., et al.
Publicado: (2014) -
Anti-Insulin Receptor Autoantibodies Are Not Required for Type 2 Diabetes Pathogenesis in NZL/Lt Mice, a New Zealand Obese (NZO)-Derived Mouse Strain
por: McInerney, Marcia F., et al.
Publicado: (2004) -
Rapamycin‐mediated mouse lifespan extension: Late‐life dosage regimes with sex‐specific effects
por: Strong, Randy, et al.
Publicado: (2020) -
Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice
por: Strong, Randy, et al.
Publicado: (2022)